Late-stage MS opportunity Mapi Pharma is finalizing a Phase III lead asset GA Depot for relapsing forms of multiple sclerosis and has an exclusive licensing partnership with Mylan/Viatris. This presents a near-term co-commercial or license-based sales opportunity for late-stage MS markets and expansion into PPMS.

Depot tech leverage The company specializes in long-acting depot injectables with a pipeline spanning MS, diabetes, Parkinson’s, and neuropsychiatric indications. Sales potential lies in strategic partnerships for depot formulations of GLP-1 therapies, cariprazine, and other high-barrier, high-value generics.

Strategic partnerships Mapi is actively seeking strategic partners for its depot platforms and has expressed interest in collaboration for late-stage assets and additional depot products, creating multiple partnership entry points across neurology, endocrinology, and psychiatry.

Regional capabilities With headquarters and R&D in Israel and manufacturing capacity including aseptic Fill & Finish in Jerusalem, Mapi offers integrated development-to-commercialization capabilities as a potential regional partner or contract manufacturing/procurement option for global distributors seeking depot injectable solutions.

Events and visibility Active participation in major conferences (ASCO, ADA, AAN, ACTRIMS) signals ongoing data generation and market validation, suggesting opportunities to align sales outreach with upcoming data readouts, partnerships, or licensing discussions timed to these events.